Due to developments in science and biotechnology, the concept of ‘gene doping’ is emerging as the number one threat to fair play in sport. This procedure, which involves the manipulation of one’s natural genetic characteristics in order to enhance athletic ability, has been banned by the World Anti-Doping Agency since 2003. Given the irreversible and potentially undetectable nature of this nascent form of enhancement, it is clear that gene doping poses one of the toughest challenges that anti-doping authorities have yet to face. By adopting an inter-disciplinary approach to the issue that focuses on the scientific, legal, practical and ethical issues associated with this pre-emptive prohibition of gene doping, this article arrives at a somewhat inflammatory and provocative conclusion: it might be time for sport’s stakeholders to consider allowing—and regulating to a safe level—the use of genetic modification in sport. The future of cheating in sport is upon us, and the time to act is now.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Former director at the National Centre for Human Genome and co-discoverer of the structure of DNA (alongside Francis Crick) in 1953.
Dimeo (2007, p. 130).
See Anderson (2018), noting that gene doping is a ‘21st-century means of cheating in sport’.
Custer (2007, p. 185).
Pound’s introductory comments at the Banbury Workshop are helpfully printed in Schneider and Friedmann (2006, pp. 66–72).
National Human Genome Research Institute (2018).
Wright (2006, p. 334).
Harridge and Velloso (2009, p. 378).
Sporadic references to germ-line modification are made where appropriate (such as in Chapter 3.2).
World Anti-Doping Agency (2018a).
See generally Schuelke et al. (2004).
Schjerling (2005, pp. 25–26).
Jones et al. (2002).
van der Gronde et al. (2013, p. 678).
Boxing provides a particularly interesting case study because scientific evidence has suggested that manipulation of the DREAM gene could lead to the ability to feel less pain caused by injury. See Cheng and Penninger (2003).
See Unal and Unal (2004, p. 358).
Haisma and de Hon (2006, pp. 259–260).
Wells (2008, p. 624).
van der Gronde et al. (2013, p. 671).
Hacein-Bey-Abina et al. (2002).
Wells (2008, p. 624).
Wells (2009, p. 169).
Reiss and Straughan (1996, p. 37).
Artioli et al. (2007, p. 350).
Gatzidou et al. (2009, p. 42).
Wang et al. (2013).
Friedmann and Hoffman (2009, p. 246) (noting the reports of patients who developed cancer because of the retrovirus insertions).
Polcz and Lewis (2018, p. 9).
Ginn et al. (2018, p. 4).
Steiner (2011, p. 88).
Murray (2017, p. 465).
Miah (2005, p. 43) (citing David Powell, Spectre of Gene Doping Raises its Head as Athletes see Possibilities (2001) The Times, London).
See, for example, Friedmann et al. (2010, p. 647) (discussing the allegations that a Chinese genetics laboratory offered athletes the chance to genetically modify themselves before the 2008 Beijing Olympic Games).
Schneider and Friedmann (2006, p. 37).
World Anti-Doping Agency (2008).
Todd and Todd (2009, p. 65) (highlighting that ‘[f]ans likes to see record lifts and our lifters like to make record lifts’).
Miah (2004a, p. 54).
For background, see Fotheringham (2017).
Ritchie (2015, p. 280).
Brzezianska et al. (2014, p. 253).
Fischetto and Bermon (2013, pp. 973–974).
Ibid. However, c/f Guescini et al. (2007).
International Olympic Committee (2016).
See generally Baoutina et al. (2010).
Beiter et al. (2011, p. 228).
Fischetto and Bermon (2013, p. 974).
Wells (2008, p. 629). See also the discussion of Finnish skier Eero Maentyranta in Chapter 4.2.
Jakobsson et al. (2006).
CAS 94/129, USA Shooting & Quigley v UIT, para 34.
Fore (2010, p. 81).
Schmalzer (2009, pp. 690–691) (paraphrasing one French official).
On this point, see Chapter 3.2.
Munthe (2005, p. 112).
Miah (2004a, p. 145).
See generally Simon et al. (2018, chapter 4).
van Hilvoorde (2005, p. 94).
Donovan (2009, p. 119).
Hoberman (2009, p. 7).
Holt and Sonksen (2008, p. 543).
Mehlman (2009, p. 220).
See generally Tamburrini (2005, pp. 86–87).
However, note the recent reports from the genetic sequencing giant Illumina that it may soon be able to sequence an entire human genome for as little as $100: Keshavan (2017).
Custer (2007, p. 204).
World Anti-Doping Agency (2015), Article 2.5 (tampering with doping control); Article 2.6 (possession of a prohibited substance/method). See also Article 3.2 where it is stated that ‘[f]acts related to anti-doping rule violations may be established by any reliable means’ [emphasis added].
CAS 2004/O/645, USADA v Montgomery.
Ibid, para 36. However, see the comments made in CAS 2015/A/4059, WADA v Thomas Bellchambers et al, AFL and ASDA where the CAS panel, at para 105, refused to accept that there is ‘no material difference between proof beyond a reasonable doubt and proof of comfortable satisfaction’. The dictum in Montgomery, they argue, was case specific.
CAS 2004/A/651, French v Australian Sports Commission & Cycling Australia. See also USADA v Leogrande, AAA Panel Decision dated 1 December 2008 (admission of doping, alongside clear circumstantial evidence, was enough to establish an ADRV).
USADA v Collins, AAA Panel Decision dated 9 December 2004 suggests that it might.
Bellchambers (See n85), para 144.
CAS 2004/0/649, USADA v Gaines. See also USADA v Armstrong (Decision of USADA on disqualification and ineligibility, dated 10 October 2012).
McLaren (2006, pp. 198–203).
Knowles (2007, p. 246).
Wilson (2009, pp. 152–153).
Friedmann and Hoffman (2009, pp. 242–243).
van Hilvoorde et al. (2007, p. 191).
Schneider and Friedmann (2006, pp. 29–31).
Ibid. See also Hacein-Bey-Abina et al. (2003).
Gao et al. (2004).
Momaya et al. (2017, p. 484).
Simon (2016, pp. 98–99).
See generally Okrent (2011).
Coffey (1975, pp. 196–198).
Savulescu et al. (2004, p. 669).
Cooper (2012, pp. 220–221).
van der Gronde et al. (2013, p. 673).
Cooper (2012, p. 227).
Slavicek (2008, p. 7).
Knowles (2007, p. 246).
Although the ‘Goldman dilemma’ is a ‘significant piece of evidence’ that remains ‘one of the most cited results in the anti-doping literature’, some authors have questioned its credibility. For example, Connor et al. 2013 highlight various weaknesses in the work including: the wording of the questions, the use of the question method, generalisability over different times and contexts, and no comparable measure of acceptance among the general population. See also Woolf et al. (2017).
Goldman et al. (1984, p. 32).
Connor and Mazanov (2009, pp. 871–872).
For an excellent and engaging discussion of this ‘game theory’ as applied to law, see Farnsworth (2007, pp. 100–109).
See generally Haugen (2004).
Schneider and Friedmann (2006, p. 47).
Anderson (2013, p. 152).
For background on Fuentes and the surrounding ‘Operacion Puerto’, see Hardie (2011, p. 160).
Green (2009, pp. 84–85).
Juengst (2009, p. 184).
Schneider (2005, p. 36).
This is a slightly reworked example taken from Custer (2007, pp. 205–206).
World Anti-Doping Agency (2018b). The other three criteria are that (1) significant health problems would arise without the substance; (2) there is no reasonable therapeutic alternative; and (3) necessity of use is not a consequence of using another prohibited substance.
The question of how long the ban would—and should—be is discussed shortly.
Hamilton (2006, p. 40). See also, at pp. 39–40, Hamilton’s discussion of ‘Tommy John surgery’ which can also be used to enhance athletic performance.
Lewis (2013, p. 733).
Miah (2010, p. 224).
Filipp (2007, p. 434).
WADA (See n14), section S8.
CAS OG/98/002, Rebagliati v IOC, para 26.
See generally Houlihan (2002, pp. 91–92, 110).
Schneider and Friedmann (2006, pp. 33–34).
Viret (2015, p. 445).
Sinex and Chapman (2015).
See the most recent discussion in Murray (2018, pp. 139–144).
WADA (See n83), Article 4.3.1.
Ibid, Article 220.127.116.11 - 18.104.22.168.
Miah (2004a, p. 36).
Hoberman (1992, p. 104).
Sigman (2008, p. 133).
Lin and Allhoff (2008, pp. 252–254).
Steiner (2011, p. 69).
See generally Mundie and Jurejko (2017).
Miah (2004a, p. 98).
Murray (2018, p. 166). See also, at p. 56, where he states that ‘the line between “natural” and “unnatural” can be tough to see at times’.
Murray (2018, p. 166). He uses concepts such as ‘organic’, ‘rational’, ‘voluntary’ and ‘person’ to illustrate his point.
Ibid, p. 167.
President’s Council on Bioethics (2003).
Custer (2007, p. 208).
Quigley (See n66), para 15.
Flint (2008, pp. 835–836).
WADA (See n83) 11.
Miah (2004a, p. 166).
Anderson (2010, pp. 126–127).
Demonstrating that one bore ‘No Significant Fault or Negligence’ for their genetic modification under Article 10.5 WADC is also another possibility, but it is perhaps a less attractive one for athletes because, unlike under Article 10.4, it does not necessarily lead to an automatic elimination of the period of ineligibility. In sum, the degree of fault is assessed under Article 10.5.
CAS 2006/A/1025, Puerta v ITF, para 11.4.1.
CAS 2009/A/1296, ITF v Gasquet.
See also the more recent example of The Football Association v Livermore, 8 September 2015, where a footballer was able to avoid a ban after he successfully attributed his ingestion of cocaine to a recent family bereavement.
WADA (See n83) 63.
The refusal to allow Article 10.4 to operate in such scenarios is to cater for those situations where an associate agrees to ‘take the fall’ for an athlete by claiming to have spiked their food or drink. See CAS 2002/A/432, D v FINA, para 9.3.11. For a more recent application which neatly highlights the strictness of this test, see CAS OG 16/25, WADA v Narsingh Yadav & NADA.
McArdle (2015, p. 300) [emphasis added].
See CAS 2005/C/976 & 986, FIFA & WADA, Advisory Opinion, para 73.
CAS 2006/A/1041, Vassilev v FIBT & BBTF.
CAS 2005/A/990, Pobyedonostsev v IIHF. For commentary on this case, see David (2017, pp. 390–391).
Ibid, para 36.
WADA (See n83), Article 3.1.
See Chapter 4.2.
This is also a solution proposed by Anderson (2016, pp. 265–266).
See text to n266. Given that WADA is a private foundation with no authority to target companies and individuals who have not submitted to sports regulations, such cooperation would be key.
Digital, Culture, Media and Sport Committee (2018).
Noakes (2006, p. 289).
Gardiner et al. (2012, p. 68).
Craik (2011, p. 73).
Quinn (2002, p. 186).
Craik (2011, p. 72).
Miah (2004a, p. xviii).
Magdalinski and Brooks (2002).
See, for example, Miah (2004a, pp. 53–54) (stating that media attention surrounding gene doping has been ‘sensationalistic and has sought to ground hysteria about the possibility for creating superhumans in sport’).
Tamburrini and Tannsjo (2005, p. 1).
Sandel (2007, p. 26).
President’s Council on Bioethics (See n164), p. 142.
See, for example, Nuffield Council on Bioethics (2002).
See Schneider 2005, p. 36 (arguing that ‘the way in which the public will treat gene transfer technology if and when it becomes readily available is unknown’).
Polcz and Lewis (2018, pp. 5, 39–40).
Ibid, pp. 25–26.
Ibid, p. 32.
The citizens of East Germany, China and Russia, for example, may all have radically different views on the potential legalisation of gene doping in their respective countries.
Miah (2004a, p. 177).
See text to n137.
See generally Breivik (2005, p. 175).
Posner (2008, p. 1734).
See Griffith-Jones (1997, p. vii).
Dimeo and Moller (2018, p. 24).
Ibid, pp. 29–33.
Custer (2007, p. 197).
Ashworth (2013, p. 77).
Miah (2004a, p. 171).
Polcz and Lewis (2018, p. 33). Interestingly, 29% were in favour of legalisation when the substance was simply referred to as a “drug”.
Smith and Stewart (2008, p. 124).
Petersen and Kristensen (2009, p. 97).
Dabholkar (2013, p. 58).
Savulescu et al. (2004, p. 667).
Simon (2016, p. 103).
Savulescu et al. (2004, p. 667).
Frias (2016, p. 107).
Juengst (2009, pp. 198–199).
Varley et al. (2018, p. 16).
Ibid, p. 68; van Hilvoorde (2005, pp. 98–99) (stating that ‘admiration of athletes will… be concentrated on the sacrifices endured to actualize their genetic predisposition’).
See generally Tamburrini (2007).
Murray (2018, p. 16).
Murray (2009b, p. 230).
American Academy of Neurology (2014).
On this point, see also the related discussion surrounding the existence of the so-called brain doping amongst athletes, a technique that uses electrical stimulation to help make it easier to learn new sporting skills and reduce fatigue. If this were possible, it would mean that even admired personality traits could be modified independently from the question of genetics. See Reardon 2016.
See text to n22.
Allison (2005, p. 153).
Loland (2005) skilfully outlines this distinction in his so-called vulnerability thesis.
Tamburrini (2007, p. 261).
van Hilvoorde (2005, p. 96).
Carr (2000, p. 2).
Miah (2004a, p. 36).
Cooper (2012, p. 220).
Murray (2018, p. 75).
Bacalao-Fleury (2011, p. 207).
Onywera (2009, p. 106).
Fore (2010, p. 93).
Athletes who exhibit levels of gene expression that are above what could be considered ‘safe’ should be prevented from competing.
International Association of Athletics Federations (2018).
See Murray (2018, p. 14) (noting that in American football ‘wide receivers can weigh half as much as offensive linemen, but they need to be fast, elusive, have great hands and the courage to catch a pass knowing they’re likely to get hit’).
Ibid, p. 30.
Murray (2009b, pp. 227–228).
Buckley (2008, p. 90).
Anderson (2010, p. 167).
As Anderson (2016, p. 266) concludes, this approach would be an integrated one ‘favouring statutory “gateways” of cooperation between sports bodies and drug, law and custom enforcement agencies’.
Associated Press (1998).
Schneider and Friedmann (2006, p. 69).
Allison L (2005) Citius, altius, fortius ad absurdum: biology, performance and sportsmanship in the twenty-first century. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 149–157
American Academy of Neurology (2014) Low tolerance for pain? The reason may be in your genes. https://www.aan.com/PressRoom/Home/PressRelease/1269. Accessed 30 Nov 2018
Anderson J (2010) Modern sports law: a textbook. Hart, Oxford
Anderson J (2013) Doping, sport and the law: time for repeal of prohibition? Int J Law Context 9(2):135–159
Anderson J (2016) The juridification and criminalisation of doping: time to revive the spirit of sport? In: Haas U, Healey D (eds) Doping in sport and the law. Hart, Oxford, pp 251–268
Anderson J (2018) The future? Gene-edited athletes, eSports and the end of contact sport. https://www.irishexaminer.com/archives/2018/0510/sport/the-future-gene-edited-athletes-esports-and-the-end-of-contact-sport-470454.html. Accessed 15 Nov 2018
Artioli G, Hirata R, Lancha A (2007) Gene therapy, genetic doping and sport: fundaments and implications for the future. Rev Bras Med Esporte 13(5):349–354
Aschwanden C (2000) Gene cheats. New Sci 15:24–29
Ashworth A (2013) Principles of criminal law, 7th edn. Oxford University Press, Oxford
Associated Press (1998) Cycling: a call for doping changes. https://www.nytimes.com/1998/07/27/sports/cycling-a-call-for-doping-changes.html. Accessed 1 Dec 2018
Azzazy H (2005) Doping in the recombinant era: strategies and counterstrategies. Clin Biochem 38(11):959–965
Azzazy H, Mansour M (2007) Rogue athletes and recombinant DNA technology: challenges for doping control. Analyst 132(10):951–957
Bacalao-Fleury C (2011) Brazil’s olympic trials: an overview of the intellectual property challenges posed by the 2016 Rio de Janeiro games. U Ill J L Tech Pol 1:191–213
Baoutina A et al (2008) Developing strategies for detection of gene doping. J Gene Med 10(1):3–20
Baoutina A et al (2010) Gene doping detection: evaluation of approach for direct detection of gene transfer using erythropoietin as a model system. Gene Ther 17(8):1022–1032
Barton-Davies E et al (1998) Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Nat Acad Sci USA 95(26):15603–15607
Battery L, Solomon A, Gould D (2011) Gene doping: olympic genes for olympic dreams. J R Soc Med 104(12):494–500
BBC (2017) Is para-sport classification fit for purpose? https://www.bbc.co.uk/sport/disability-sport/41802313. Accessed 29 Nov 2018
BBC (2018) Ellie Soutter death: father criticises pressure on athletes. https://www.bbc.co.uk/news/uk-england-surrey-45023187. Accessed 5 Dec 2018
Beiter T et al (2011) Direct and long-term detection of gene doping in conventional blood samples. Gene Ther 18(3):225–231
Berthelot G et al (2015) Has athletic performance reached its peak? Sports Med 45(9):1263–1271
Bloom B (2018) WADA warns doping whistleblowers about dangers of going public. https://www.telegraph.co.uk/sport/2018/02/08/wada-warns-doping-whistleblowers-dangers-going-public. Accessed 14 Aug 2018
Bouchard T (2004) Genetic influence on human psychological traits: a survey. Curr Dir Psychol Sci 13(4):148–151
Breivik G (2005) Sport, gene doping and ethics. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 165–177
Brzezianska E, Domanska D, Jegier A (2014) Gene doping in sport—perspectives and risks. Biol Sport 31(4):251–259
Buckley J (2008) Classification and the games. In: Gilbert K, Schantz O (eds) The paralympic games: empowerment or side show?. Meyer & Meyer, Maidenhead, pp 90–101
Campos D, Yonamine M, Moreau R (2003) Marijuana as doping in sports. Sports Med 33(6):395–399
Carr C (2000) On fairness. Ashgate, Aldershot
Catlin D, Murray T (1996) Performance-enhancing drugs, fair competition, and olympic sport. JAMA 276(3):231–237
Chadwick R, Wilson S (2005) Bio-amazons—a comment. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 205–208
Cheng H, Penninger J (2003) When the DREAM is gone: from basic science to future prospectives in pain management and beyond. Expert Opin Ther Targets 7(2):249–263
Coffey T (1975) The long thirst: prohibition in America, 1920–1933. Norton, New York
Conn D (2017) ‘Football’s Biggest Issue’: the struggle facing boys rejected by academies. https://www.theguardian.com/football/2017/oct/06/football-biggest-issue-boys-rejected-academies. Accessed 5 Dec 2018
Connor J, Mazanov J (2009) Would you dope? A general population test of the Goldman dilemma. Br J Sports Med 43(11):871–872
Connor J, Woolf J, Mazanov J (2013) Would they dope? Revisiting the Goldman dilemma. Br J Sports Med 47(11):697–700
Cooper C (2012) Run, swim, throw, cheat: the science behind drugs in sport. Oxford University Press, Oxford
Craik J (2011) The fastskin revolution: from human fish to swimming androids. Cult Unbound 3(1):71–82
Custer K (2007) From mice to men: genetic doping in international sports. Hastings Int Comp Law Rev 30:181–210
Dabholkar S (2013) A need to intercede? The international olympic committee and intersexuality. Int Sports Law J 13(1):55–59
David P (2017) A guide to the world anti-doping code: the fight for the spirit of sport, 3rd edn. Cambridge University Press, Cambridge
Desgorces F et al (2008) From Oxford to Hawaii: ecophysiological barriers limit human progression in ten sport monuments. PLoS ONE 3(11):e3653
Dierickx K, Deckx S, Hens K (2012) The ethics of gene doping: a survey of elite athletes and academic professionals. J Clin Res Bioeth 3(2):136–140
Digital, Culture, Media and Sport Committee (2018) Combatting doping in sport: fourth report of session 2017–2019, pp. 42–43. https://publications.parliament.uk/pa/cm201719/cmselect/cmcumeds/366/366.pdf. Accessed 6 Nov 2018
Dimeo P (2007) A history of drug use in sport 1876–1976: beyond good and evil. Routledge, London
Dimeo P, Moller V (2018) The anti-doping crisis in sport: causes, consequences, solutions. Routledge, London
Donovan R (2009) Toward an understanding of factors influencing athletes’ attitudes about performance-enhancing technologies: implications for ethics education. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 111–140
ESPN (2015) WADA wants funding to keep pace with Rooney-style wage rises. http://www.espn.co.uk/olympics/story/_/id/13310936/wayne-rooney-earns-much-world-anti-doping-agency-annual-budget-which-struggling-catch-drugs-cheats-due-lack-funds. Accessed 11 Sept 2018
Fainaru-Wada M, Williams L (2006) Game of shadows. Penguin, London
Farnsworth W (2007) The legal analyst: a toolkit for thinking about the law. University of Chicago Press, Chicago
Farrey T (2017) Have adults ruined children’s sport? https://www.bbc.co.uk/news/world-us-canada-42329564. Accessed 5 Dec 2018
Filipp F (2007) Is science killing sport? Gene therapy and its possible abuse in doping. EMBO Rep 8(5):433–435
Fischetto G, Bermon S (2013) From gene engineering to gene modulation and manipulation: Can we prevent or detect gene doping in sports? Sports Med 43(10):965–977
Flint C (2008) Drug use in sport: the regulatory framework. In: Lewis A, Taylor J (eds) Sport: law and practice, chapter E1, 2nd edn. Tottel Publishing, London
Food Standards Agency (2018) Genetically modified foods. https://www.food.gov.uk/safety-hygiene/genetically-modified-foods. Accessed 10 Nov 2018
Fore J (2010) Moving beyond “gene doping”: preparing for genetic modification in sport. Va J L Tech 15(1):76–100
Foster L, James D, Haake S (2012) Influence of full body swimsuits on competitive performance. Procedia Eng 34:712–717
Fotheringham W (2000) Boardman quitting to take drugs. https://www.theguardian.com/sport/story/0,3604,380917,00.html. Accessed 10 Nov 2018
Fotheringham A (2017) The end of the road: the festina affair and the tour that almost wrecked cycling. Bloomsbury, London
Franks T (2014) Gene doping: sport’s biggest battle? https://www.bbc.co.uk/news/magazine-25687002. Accessed 10 Nov 2018
Frias F (2016) The defining components of the cyborg: cyborg-athletes, fictional or real? Sport Ethics Philos 10(1):97–111
Friedmann T, Hoffman E (2009) Genetic doping in sport: applying the concepts and tools of gene therapy. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 241–254
Friedmann T, Rabin O, Frankel M (2010) Gene doping and sport. Science 327(5966):647–648
Gao G et al (2004) Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103(9):3300–3302
Gardiner S et al (2012) Sports law, 4th edn. Routledge, London
Gatzidou E, Gatzidou G, Theocharis S (2009) Genetically transformed world records: a reality or in the sphere of fantasy? Med Sci Monit 15(2):41–47
Ginn S et al (2018) Gene therapy clinical trials worldwide to 2017: an update. J Gene Med 20(5):1–16
Goldman B, Bush P, Klatz R (1984) Death in the locker room: steroids in sport. Icarus Press, South Bend
Green G (2009) The role of physicians, scientists, trainers, coaches, and other nonathletes in athletes’ drug use. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 81–96
Greif K, Merz J (2007) Current controversies in the biological sciences: case studies of policy challenges from new technologies. MIT Press, Cambridge
Griffith-Jones D (1997) Law and the business of sport. Butterworths, London
Guescini M et al (2007) Fine needle aspiration coupled with real-time PCR: a painless methodology to study adaptive functional changes in skeletal muscle. Nutr Metab Cardiovasc Dis 17(5):383–393
Hacein-Bey-Abina S et al (2002) Sustained correction of x-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346(16):1185–1193
Hacein-Bey-Abina S et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-XI. Science 302(5644):415–419
Hadhazy A (2008) What makes michael Phelps so good? https://www.scientificamerican.com/article/what-makes-michael-phelps-so-good1/. Accessed 24 Oct 2018
Haisma H, de Hon O (2006) Gene doping. Int J Sports Med 27(4):257–266
Hamilton M (2006) Elective performance enhancement surgery for athletes: Should it be resisted? Acta Univ Palacki Olous Gymn 36(2):39–46
Hamlyn P (2001) Gene genie casts ominous shadow. https://www.telegraph.co.uk/sport/othersports/drugsinsport/3018080/Gene-genie-casts-ominous-shadow.html. Accessed 23 Aug 2018
Hardie M (2011) It’s not about the blood! Operacion Puerto and the end of modernity. In: McNamee M, Moller V (eds) Doping and anti-doping policy in sport: ethical, legal and social perspectives. Routledge, London, pp 160–182
Harridge S, Velloso C (2009) IGF-I and GH: potential use in gene doping. Growth Horm IGF Res 19(4):378–382
Haugen K (2004) The performance-enhancing drug game. JSE 5(1):67–86
Heinz G, Mashreghi M (2017) CRISPR-Cas system as molecular scissors for gene therapy. Z Rheumatol 76(1):46–49
Ho M (1998) Genetic engineering—dream or nightmare? The brave new world of bad science and big business. Gateway, Bath
Hoberman J (1992) Mortal engines: the science of performance and the dehumanization of sport. Free Press, New York
Hoberman J (2009) Putting doping into context: historical and cultural perspectives. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 3–27
Holt R, Sonksen P (2008) Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol 154(3):542–556
Houlihan B (2002) Dying to win: doping in sport and the development of anti-doping policy, 2nd edn. Council of Europe, Strasbourg
Ingle S (2018) Sport’s war on drugs is being lost on many fronts. https://www.theguardian.com/sport/2018/jul/09/wada-anti-doping?CMP=Share_iOSApp_Other. Accessed 9 Sept 2018
International Association of Athletics Federations (2018) IAAF response to open letter from the Women’s Sports Foundation and Athlete Ally. https://www.iaaf.org/news/press-release/iaaf-response-to-womens-sports-foundation-and. Accessed 17 Aug 2018
International Olympic Committee (2002) WADA and IOC publish new list of banned substances and methods. https://www.olympic.org/news/wada-and-ioc-publish-new-list-of-banned-substances-and-methods-1. Accessed 16 Nov 2018
International Olympic Committee (2016) Olympic movement medical code, Chapter 1.3. https://stillmed.olympic.org/media/Document%20Library/OlympicOrg/IOC/Who-We-Are/Commissions/Medical-and-Scientific-Commission/Olympic-Movement-Medical-Code-31-03-2016.pdf#_ga=2.33760802.2007459810.1529939714-1593240879.1529939714. Accessed 27 Oct 2018
Jakobsson J et al (2006) Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 91(2):687–693
Jones A, Montgomery H, Woods D (2002) Human performance: a role for the ACE genotype? Exerc Sport Sci Rev 30(4):184–190
Juengst E (2009) Annotating the moral map of enhancement: gene doping, the limits of medicine, and the spirit of sport. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 175–204
Juhn M (2003) Popular sports supplements and ergogenic aids. Sports Med 33(12):921–939
Kaebnick G (2013) Humans in nature: the world as we find it and the world as we create it. Oxford University Press, Oxford
Kaiser J (2015) CRISPR helps heal mice with muscular dystrophy. http://www.sciencemag.org/news/2015/12/crispr-helps-heal-mice-muscular-dystrophy. Accessed 4 Oct 2018
Karp H (2011) Novak Djokovic’s secret: sitting in a pressurized egg. https://www.wsj.com/articles/SB10001424053111904787404576532854267519860. Accessed 3 Dec 2018
Keshavan M (2017) Illumina says it can deliver a $100 genome—soon. https://www.statnews.com/2017/01/09/illumina-ushering-in-the-100-genome. Accessed 10 Aug 2018
Knapton S (2015) Intelligence genes discovered by scientists. https://www.telegraph.co.uk/news/science/science-news/12061787/Intelligence-genes-discovered-by-scientists.html. Accessed 3 Dec 2018
Knight T (2004) Inside information gives drug investigators shot in the arm. https://www.telegraph.co.uk/sport/othersports/athletics/2383957/Inside-information-gives-drug-investigators-shot-in-the-arm.html. Accessed 15 Nov 2018
Knowles E (2007) Oxford dictionary of modern quotations, 3rd edn. Oxford University Press, Oxford
Lee S et al (2004) Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J Appl Physiol 96(3):1097–1104
Lewis S (2013) Man, machine, or mutant: when will athletes abandon the human body? Jeffrey S Moorad Sports L J 20(2):717–772
Lin P, Allhoff F (2008) Untangling the debate: the ethics of human enhancement. Nanoethics 2(3):251–264
Lippi G, Guidi G (2004) Gene manipulation and improvement of athletic performances: new strategies in blood doping. Br J Sports Med 38(5):641
Loland S (2005) The vulnerability thesis and use of bio-medical technology in sport. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 158–164
Loland S, Caplan A (2008) Ethics of technologically constructed hypoxic environments in sport. Scand J Med Sci Sports 18(Suppl 1):70–75
Loland S, Murray T (2007) The ethics of the use of technologically constructed high-altitude environments to enhance performances in sport. Scand J Med Sci Sports 17(3):193–195
Lopez B (2017) From needle phobia to doping phobia: Can the fear of injections help us understand anti-dopism? Drug Educ Prev Policy 24(3):314–320
Magdalinski T, Brooks K (2002) Bride of Frankenstein: technology and the consumption of the female athlete. In: Miah A, Eassom S (eds) Sport technology: history, philosophy and policy. Elsevier, Amsterdam, pp 195–212
Mallea P (2014) The war on drugs: a failed experiment. Dundurn Press, Toronto
Matthews G (2005) America’s first olympics. University of Missouri Press, Missouri
McArdle D (2015) ‘Strict liability’ and legal rights: nutritional supplements, ‘intent’ and ‘risk’ in the parallel world of WADA. In: Moller V, Waddington I, Hoberman J (eds) Routledge handbook of drugs and sport. Routledge, London, pp 293–309
McCrory P (2003) Super athletes or gene cheats? Br J Sports Med 37(3):192–193
McKanna T, Toriello H (2010) Gene doping: the hype and the harm. Pediatr Clin N Am 57(3):719–727
McLaren R (2006) An overview of non-analytical positive and circumstantial evidence cases in sports. Marq Sports L Rev 16(2):193–212
Mehlman M (2009) Genetic enhancement in sport: ethical, legal and policy concerns. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 205–224
Miah A (2004a) Genetically modified athletes: biomedical ethics, gene doping and sport. Routledge, London
Miah A (2004) Genetically modified athletes in Athens? Bring them on. https://www.theguardian.com/sport/2004/aug/01/athletics.athensolympics20042. Accessed 29 Oct 2018
Miah A (2005) Gene doping: the shape of things to come. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 42–53
Miah A (2010) Towards the transhuman athlete: therapy, non-therapy and enhancement. Sport Soc 13(2):221–233
Miller K et al (2016) Cancer treatment and survivorship statistics. CA Cancer J Clin 66(4):271–289
Momaya A, Fawal M, Estes R (2017) Performance-enhancing substances in sports: a review of the literature. In: Caplan A, Parent B (eds) The ethics of sport: essential readings. Oxford University Press, Oxford, pp 468–493
Mottram D (2015) The evolution of doping and anti-doping in sport. In: Mottram D, Chester N (eds) Drugs in sport, 6th edn. Routledge, London, pp 21–36
Mundie S, Jurejko J (2017) State of sport: FIFA’s former doctor says painkiller use risks footballers’ health. https://www.bbc.co.uk/sport/39333763. Accessed 13 Dec 2018
Munthe C (2000) Selected champions: making winners in the age of genetic technology. In: Tannsjo T, Tamburrini C (eds) Values in sport: elitism, nationalism, gender equality, and the scientific manufacturing of winners. Taylor & Francis, Oxford, pp 217–231
Munthe C (2005) Ethical aspects of controlling genetic doping. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 107–125
Murray T (2009a) Ethics and endurance-enhancing technologies in sport. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 141–159
Murray T (2009b) In search of an ethics for sport: genetic hierarchies, handicappers general, and embodied excellence. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 225–238
Murray T (2017) Sports enhancement. In: Caplan A, Parent B (eds) The ethics of sport: essential readings. Oxford University Press, Oxford, pp 459–467
Murray T (2018) Good sport: why our games matter—and how doping undermines them. Oxford University Press, Oxford
National Human Genome Research Institute (2018) Somatic cells. https://www.genome.gov/glossary/index.cfm?id=186. Accessed 1 August 2018
Noakes T (2006) Should we allow performance-enhancing drugs in sport? A rebuttal to the article by Savulescu and colleagues. Int J Sports Sci Coach 1(4):289–316
Nuffield Council on Bioethics (2002) The ethics of patenting DNA, paras 3.3–3.7. http://nuffieldbioethics.org/wp-content/uploads/2014/07/The-ethics-of-patenting-DNA-a-discussion-paper.pdf. Accessed 16 Aug 2018
O’Mahony P (2008) The Irish war on drugs: the seductive folly of prohibition. Manchester University Press, Manchester
Okrent D (2011) Last call: the rise and fall of prohibition. Scribner, New York
Onywera V (2009) East African runners: their genetics, lifestyle and athletic prowess. In: Collins M (ed) Genetics and sport. Karger, Basel, pp 102–109
Ostrander E, Huson H, Ostrander G (2009) Genetics of athletic performance. Ann Rev Genomics Hum Genet 10:407–429
Petersen T, Kristensen J (2009) Should athletes be allowed to use all kinds of performance-enhancing drugs? A critical note on Claudio M. Tamburrini. J Philos Sport 36(1):88–98
Polcz S, Lewis A (2016) CRISPR-Cas9 and the non-germline non-controversy. JLB 3(2):413–425
Polcz S, Lewis A (2018) Regulating genetic advantage. Harv J L & Tech (forthcoming). https://law.stanford.edu/publications/regulating-genetic-advantage
Posner R (2008) In defense of Prometheus: some ethical, economic, and regulatory issues of sports doping. Duke Law J 57(6):1725–1741
President’s Council on Bioethics (2003) Beyond therapy: biotechnology and the pursuit of happiness, p. 122. https://biotech.law.lsu.edu/research/pbc/reports/beyondtherapy/beyond_therapy_final_report_pcbe.pdf. Accessed 27 Oct 2018
Quinn B (2002) Techno fashion. Berg, Oxford
Reardon S (2016) ‘Brain doping’ may improve athletes’ performance. Nature 531(7594):283–284
Reiss M, Straughan R (1996) Improving nature? The science and ethics of genetic engineering. Cambridge University Press, Cambridge
Reynolds G (2007) Outlaw DNA. https://www.nytimes.com/2007/06/03/sports/playmagazine/0603play-hot.html. Accessed 20 Sept 2018
Ritchie I (2015) Understanding performance-enhancing substances and sanctions against their use from the perspective of history. In: Moller V, Waddington I, Hoberman J (eds) Routledge handbook of drugs and sport. Routledge, London, pp 20–30
Robinson N et al (2011) The athlete biological passport: an effective tool in the fight against doping. Clin Chem 57(6):830–832
Saletan W (2005) The beam in your eye: if steroids are cheating, why isn’t LASIK? http://www.slate.com/articles/health_and_science/human_nature/2005/04/the_beam_in_your_eye.html?via=gdpr-consent. Accessed 26 Nov 2018
Sandel M (2007) The case against perfection. Harvard University Press, Cambridge
Saugy M et al (2006) Cannabis and sport. Br J Sports Med 40(Suppl 1):i13–i15
Savulescu J, Foddy B, Clayton M (2004) Why we should allow performance enhancing drugs in sport. Br J Sports Med 38(6):666–670
Schjerling P (2005) The basics of gene doping. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 19–31
Schmalzer B (2009) A vicious cycle: the biological passport dilemma. Univ Pittsbg Law Rev 70:677–700
Schneider A (2005) Genetic enhancement of athletic performance. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 32–41
Schneider A, Friedmann T (2006) Gene doping in sports: the science and ethics of genetically modified athletes. Elsevier Academic Press, California
Schuelke M et al (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. NEJM 350(26):2682–2688
Scott-Elliott R (2014) I had to go into hiding, says drug test whistle–blower Renee–Anne Shirley. https://www.independent.co.uk/sport/general/athletics/i-had-to-go-into-hiding-says-drug-test-whistle-blower-renee-anne-shirley-9203734.html. Accessed 27 Nov 2018
Seaton M (2005) What is lance Armstrong’s secret? https://www.theguardian.com/science/2005/jul/28/thisweekssciencequestions3. Accessed 20 Oct 2018
Sherwin S, Schwartz M (2005) Resisting the emergence of bio-amazons. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 199–204
Sigman S (2008) Are we all dopes? A behavioral law and economics approach to legal regulation of doping in sports. Marq Sports L Rev 19(1):125–208
Simon R (2016) The ethics of sport. Oxford University Press, Oxford
Simon R, Torres C, Hager P (2018) Fair play: the ethics of sport, 4th edn. Routledge, London
Sinex J, Chapman R (2015) Hypoxic training methods for improving endurance exercise performance. SHS 4(4):325–332
Sinn P, Sauter S, McCray P (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors—design, biosafety, and production. Gene Ther 12(14):1089–1098
Siprashvili Z, Khavari P (2004) Lentivectors for regulated and reversible cutaneous gene delivery. Mol Ther 9(1):93–100
Slavicek L (2008) The prohibition era: temperance in the United States. Chelsea House Publishers, New York
Smith A, Stewart B (2008) Drug policy in sport: hidden assumptions and inherent contradictions. Drug Alcohol Rev 27(2):123–129
Smithers R (2013) Two thirds of British consumers say GM food labelling is important. https://www.theguardian.com/environment/2013/jan/09/consumers-gm-food-labelling. Accessed 10 Nov 2018
Sottas P et al (2011) The athlete biological passport. Clin Chem 57(7):969–976
Stefani R (2012) Olympic swimming gold: the suit or the swimmer in the suit? Significance 9(2):13–17
Steiner J (2011) Genetic doping: the Lance Armstrong case as a preview for future regulations. Ariz St U Sports Ent L J 1(2):41–92
Tamburrini C (2005) Educational or genetic blueprints, what’s the difference? In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 82–90
Tamburrini C (2007) After doping, what? The morality of the genetic engineering of athletes. In: Morgan W (ed) Ethics and sports, 2nd edn. Human Kinetics, Champaign, pp 285–297
Tamburrini C, Tannsjo T (2005) Introduction: the life sciences and the ethos of sport. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 1–10
Tannsjo T (2005) Genetic engineering and elitism in sport. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 57–69
The Economist (2016) The Rio Paralympics were successful, but the disability classifications are not. https://www.economist.com/game-theory/2016/09/21/the-rio-paralympics-were-successful-but-the-disability-classifications-are-not. Accessed 29 Nov 2018
Todd J, Todd T (2009) Reflections on the “parallel federation solution” to the problem of drug use in sport: the cautionary tale of powerlifting. In: Murray T, Maschke K, Wasunna A (eds) Performance-enhancing technologies in sports: ethical, conceptual and scientific issues. John Hopkins University Press, Baltimore, pp 44–80
Unal M, Unal D (2004) Gene doping in sports. Sports Med 34(6):357–362
van der Gronde T et al (2013) Gene doping: an overview and current implications for athletes. Br J Sports Med 47(11):670–678
van Hilvoorde I (2005) Sport and genetics: moral and educational considerations regarding ‘athletic predestination’. In: Tamburrini C, Tannsjo T (eds) Genetic technology and sport: ethical questions. Routledge, London, pp 91–104
van Hilvoorde I, Vos R, de Wert G (2007) Flopping, klapping and gene doping: dichotomies between ‘natural’ and ‘artificial’ in elite sport. Soc Stud Sci 37(2):173–200
Varley I et al (2018) The current use, and opinions of elite athletes and support staff in relation to genetic testing in elite sport within the UK. Biol Sport 35(1):13–19
Viret M (2015) Evidence in anti-doping at the intersection of science and law. TMC Asser Press, The Hague
Wang W et al (2013) Non-viral gene delivery methods. Curr Pharm Biotechnol 14(1):46–60
Wells D (2008) Gene doping: the hype and the reality. Br J Pharmacol 154(3):623–631
Wells D (2009) Gene doping: possibilities and practicalities. In: Collins M (ed) Genetics and sport. Karger, Basel, pp 166–175
Westbury I (2017) WADA do about WADA’s bad science? http://www.sportsintegrityinitiative.com/wada-wadas-bad-science/. Accessed 6 Oct 2018
Wilson J (2009) Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96(4):151–157
Woolf J, Mazanov J, Connor J (2017) The Goldman dilemma is dead: what elite athletes really think about doping, winning, and death. Int J Sport Policy Pol 9(3):453–467
World Anti-Doping Agency (2008) Saint Petersburg declaration. https://www.wada-ama.org/en/resources/science-medicine/saint-petersburg-declaration. Accessed 2 Aug 2018
World Anti-Doping Agency (2015) World anti-doping code. https://www.wada-ama.org/en/resources/the-code/world-anti-doping-code. Accessed 28 July 2018
World Anti-Doping Agency (2018a) Prohibited list. https://www.wada-ama.org/en/resources/science-medicine/prohibited-list-documents, section M3. Accessed 17 Aug 2018
World Anti-Doping Agency (2018b) Therapeutic use exemption (TUE). https://www.wada-ama.org/en/questions-answers/therapeutic-use-exemption-tue#item-728. Accessed 14 Sept 2018
World Anti-Doping Agency (2018c) Athletes. https://www.wada-ama.org/en/athletes Accessed 13 Sept 2018
Wright W (2006) Germ-line genetic engineering and the precautionary principle. Chrestomathy 5:333–346
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
James Brown was a former LLM Sports Law (with Distinction) graduate from Nottingham Trent University and a former first-class LLB graduate from Keele University.
About this article
Cite this article
Brown, J. Genetic doping: WADA we do about the future of ‘cheating’ in sport?. Int Sports Law J 19, 258–280 (2019). https://doi.org/10.1007/s40318-019-00141-y
- Genetic modification
- Doping regulation
- Sports law